AEterna Zentaris Inc. buy marge

AETNA: Volatility on Zoptrex Results – Proceed with caution!

This stock is going to make a big move in Mai either up or down depending on the results of the data.

All the phase 2 data for zoptrex has been successful. There is seemingly no doubt within the effectiveness of zoptrex in the slightest after looking through phase 2 data. The fundamental science behind it is also sound. The risk is consistency in treatment. If alternative treatments improve the baseline skewing the results for the control the study may struggle to produce results that are statistically significant to the primary endpoint of survival. Also unlike Phase 1 studies in mice, it is harder to gauge the true extent of the stage of cancer in a patient and there are so many other intangible variables that contribute to the primary endpoint that are difficult to measure. That brings us to the point of looking at secondary endpoints for safety and and toxicity levels.

Personally I believe that even if the median survival rate isn't statistically significant, value for secondary study endpoints will be statistically significant when looking at side effects such as apotosis of white blood cells.

The extent to which the FDA will measure the value in the secondary endpoints is unknown to me though.

I think that the binary nature of the investment makes it incredibly speculative and thus intimidating but I personally like the risk profile.